NIH's Forward Funding Revolution
Shifting to 50% forward funding could decrease total active grants from 10,000 to 6,200
Early Stage Investigators without bridge funding may struggle to survive 4-year gaps between funding cycles, disproportionately affecting new researchers.
How money flows over a 5-year project period
20% of budget released each year. Creates "out-year mortgages" that tie up future budgets.
100% of 5-year budget paid upfront in Year 1. Eliminates future obligations, enables rapid pivots.
Applications divided into thirds based on committee voting
Top third - full study section review
Still eligible for funding
Not discussed, not funded
If your grant falls in the middle tier, contact your Program Officer to explain how you'll use the lump sum to front-load high-impact equipment or data collection in Year 1.
Note: NIH no longer permits paylines - each funding decision must be individually justified.
DrugMonkey's "spherical cow" analysis: Assuming 400 total R01s with 100 expiring annually
Percentile at NCI (end of FY2025) - down from ~7th percentile
Expected success rate, down from ~20% in recent years
Data sources: Former NIGMS Director Jeremy Berg analysis, DrugMonkey analysis, NIH policy documents